AR052339A1 - Formulaciones terapeuticas del factor de crecimiento queratinocitico - Google Patents

Formulaciones terapeuticas del factor de crecimiento queratinocitico

Info

Publication number
AR052339A1
AR052339A1 ARP050105231A ARP050105231A AR052339A1 AR 052339 A1 AR052339 A1 AR 052339A1 AR P050105231 A ARP050105231 A AR P050105231A AR P050105231 A ARP050105231 A AR P050105231A AR 052339 A1 AR052339 A1 AR 052339A1
Authority
AR
Argentina
Prior art keywords
growth factor
queratinocitic
therapeutic formulations
lyophilized
keratinocyte growth
Prior art date
Application number
ARP050105231A
Other languages
English (en)
Inventor
Michael J Treuheit
Vasumathi Dharmavaram
Judith Purtell
Suzanne E Roy
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR052339A1 publication Critical patent/AR052339A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formulaciones estables y duraderas del factor de crecimiento queratinocítico liofilizado y métodos para elaborar una composicion liofilizada que comprende el factor de crecimiento queratinocítico. Reivindicacion 1: Una composicion del factor de crecimiento queratinocítico [KGF, por sus siglas en inglés] liofilizado, que la comprende solucion estabilizadora de histidina, un agente de carga, un azucar y un surfactante.
ARP050105231A 2004-12-15 2005-12-14 Formulaciones terapeuticas del factor de crecimiento queratinocitico AR052339A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63621004P 2004-12-15 2004-12-15
US11/302,033 US8304387B2 (en) 2004-12-15 2005-12-12 Therapeutic formulations of keratinocyte growth factor

Publications (1)

Publication Number Publication Date
AR052339A1 true AR052339A1 (es) 2007-03-14

Family

ID=36337531

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050105231A AR052339A1 (es) 2004-12-15 2005-12-14 Formulaciones terapeuticas del factor de crecimiento queratinocitico

Country Status (28)

Country Link
US (1) US8304387B2 (es)
EP (1) EP1827483B1 (es)
JP (1) JP5201992B2 (es)
KR (1) KR101283736B1 (es)
CN (1) CN101084008B (es)
AR (1) AR052339A1 (es)
AU (1) AU2005317166B2 (es)
BR (1) BRPI0519070A2 (es)
CA (1) CA2589889C (es)
CR (1) CR9246A (es)
DK (1) DK1827483T3 (es)
EA (1) EA013369B1 (es)
ES (1) ES2504441T3 (es)
HK (1) HK1115298A1 (es)
HR (1) HRP20140926T1 (es)
IL (1) IL183435A (es)
MX (1) MX2007006822A (es)
MY (1) MY145638A (es)
NO (1) NO20073629L (es)
NZ (1) NZ555503A (es)
PL (1) PL1827483T3 (es)
PT (1) PT1827483E (es)
RS (1) RS53548B1 (es)
SI (1) SI1827483T1 (es)
TW (1) TWI351966B (es)
UA (1) UA88497C2 (es)
WO (1) WO2006065861A2 (es)
ZA (1) ZA200706095B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304387B2 (en) 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
US20090186805A1 (en) * 2006-07-06 2009-07-23 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CN107041948A (zh) * 2009-01-21 2017-08-15 北京三有利科技发展有限公司 细胞生长因子治疗溃疡性疾病和肺纤维化疾病的应用
IT1396020B1 (it) * 2009-10-16 2012-11-09 Fitologica Srl Composizione topica a base di biopeptidi, e suo utilizzo in campo tricologico.
CN102675449B (zh) * 2011-03-17 2016-06-08 重庆富进生物医药有限公司 缺失型人角质细胞生长因子-ⅰ二硫键变构体及其用途
US20140287995A1 (en) * 2011-11-02 2014-09-25 The University Of Chicago Stable pharmaceutical formulations of growth factor peptides
CN102379838B (zh) * 2011-11-02 2013-06-12 广州舒泰生物技术有限公司 一种舒缓静颜化妆品的制备方法及应用
US20150126433A1 (en) * 2012-04-25 2015-05-07 University Of Cincinnati Growth factors for the treatment of mycobacterial infection
TWI683666B (zh) 2013-03-15 2020-02-01 美商百歐維拉提夫治療公司 因子ｉｘ多肽調配物
CN108359634A (zh) * 2018-02-02 2018-08-03 江阴司特易生物技术有限公司 一种饲养细胞蛋白复合物及其应用
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
CN110339345B (zh) * 2019-07-30 2022-11-29 重庆派金生物科技有限公司 一种重组人截短型角质细胞生长因子-1滴眼液及其制备方法和应用
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026291B1 (en) * 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
ATE197800T1 (de) * 1989-01-31 2000-12-15 Jeffrey S Rubin Dns kodierend für einen für epithelzellen spezifischen wachstumsfaktor
UA41502C2 (uk) * 1991-12-20 2001-09-17 Ново Нордіск А/С Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
CZ343795A3 (en) * 1993-06-29 1996-07-17 Chiron Corp Shortened keratinocyte growth factor /kgf/ exhibiting increased biological activity
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
HUT78069A (hu) 1994-10-13 1999-08-30 Amgen Inc. Keratinocita növekedési faktor analógok
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
CN1168678A (zh) 1994-10-13 1997-12-24 安姆根有限公司 用kgf治疗糖尿病的方法
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
CN100360184C (zh) * 1995-07-27 2008-01-09 基因技术股份有限公司 稳定等渗的冻干蛋白质制剂
WO1998024813A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives
US20020012961A1 (en) * 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
KR20010033484A (ko) * 1997-12-22 2001-04-25 휴먼 게놈 사이언시즈, 인크. 각질세포 성장 인자-2 제제
JP2003500456A (ja) * 1999-06-02 2003-01-07 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 角質細胞増殖因子−２製剤
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US8304387B2 (en) 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor

Also Published As

Publication number Publication date
KR101283736B1 (ko) 2013-07-08
NZ555503A (en) 2010-01-29
CR9246A (es) 2007-10-23
JP5201992B2 (ja) 2013-06-05
DK1827483T3 (da) 2014-10-06
IL183435A0 (en) 2007-09-20
PT1827483E (pt) 2014-09-25
CN101084008A (zh) 2007-12-05
TW200635603A (en) 2006-10-16
ES2504441T3 (es) 2014-10-08
ZA200706095B (en) 2008-09-25
BRPI0519070A2 (pt) 2008-12-23
CA2589889A1 (en) 2006-06-22
MX2007006822A (es) 2007-07-24
HK1115298A1 (en) 2008-11-28
WO2006065861A2 (en) 2006-06-22
UA88497C2 (ru) 2009-10-26
WO2006065861A3 (en) 2006-08-17
CA2589889C (en) 2013-07-30
EA200701293A1 (ru) 2008-02-28
JP2008524229A (ja) 2008-07-10
AU2005317166A1 (en) 2006-06-22
MY145638A (en) 2012-03-15
EP1827483A2 (en) 2007-09-05
US20060128622A1 (en) 2006-06-15
SI1827483T1 (sl) 2014-11-28
HRP20140926T1 (hr) 2014-11-07
US8304387B2 (en) 2012-11-06
NO20073629L (no) 2007-09-10
RS53548B1 (en) 2015-02-27
EP1827483B1 (en) 2014-07-02
CN101084008B (zh) 2013-04-10
TWI351966B (en) 2011-11-11
KR20070093977A (ko) 2007-09-19
PL1827483T3 (pl) 2014-12-31
AU2005317166B2 (en) 2009-09-10
EA013369B1 (ru) 2010-04-30
IL183435A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
AR052339A1 (es) Formulaciones terapeuticas del factor de crecimiento queratinocitico
ECSP088239A (es) Composición de liberación de fármaco sostenida
AR052545A1 (es) Suspension no acuosa inyectable
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
CL2007001185A1 (es) Formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de un conjugado de polisacarido-proteina;formulaciones que estabilizan o inhiben la agregacion inducida por silicona de una composicion de proteina de n meningitidis
BRPI0514103A (pt) dispostivo de distribuição
AR040302A1 (es) Dispositivos para la liberacion transdermica de farmacos, que presentan microprotrusiones recubiertas
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
AR033903A1 (es) Una composicion de insulina modificada quimicamente para la administracion pulmonar
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BRPI0514474A (pt) multiparticulados
AR109263A2 (es) Composición que comprende moxidectina
AR045068A1 (es) Formulacion de liberacion inmediata de composiciones farmaceuticas
MY167123A (en) Conveniently implantable sustained release drug compositions
AR064614A1 (es) Producto combinado par controlar parasitos en animales
UY30302A1 (es) Formulaciones de pepticuerpos terapeuticos liofilizados
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
AR030245A1 (es) Composiciones de gel que contienen metronidazol
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof
NO20083940L (no) Fremgangsmater for redusering av proteinaggregering
ECSP045065A (es) Queratinocitos utilizables como sustancia biológicamente activa en el tratamiento de heridas
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure